Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say

Altai Capital Management is preparing to launch a board fight at OraSure Technologies, having increased its stake from 3% to 5% to push for board representation. This activist pressure follows OraSure's 23% stock decline over the past year and its recent rejection of a buyout offer, reflecting significant investor frustration. Altai, led by Rishi Bajaj, aims to force a strategic shift at the medical device maker, potentially leveraging Bajaj's track record of driving shareholder value, as seen with his successful intervention at ContextLogic.

Analysis

Activist hedge fund Altai Capital Management is escalating its engagement with OraSure Technologies (OSUR) by increasing its stake from 3% to 5%, laying the groundwork for a proxy contest to secure board representation. This move is a direct response to significant investor frustration, which has been fueled by the stock's 23% decline over the last 12 months and the board's recent rejection of a buyout offer between $3.50 and $4.00 per share. Altai's founder, Rishi Bajaj, brings a notable track record, having previously engineered a turnaround at ContextLogic (LOGC) that resulted in its stock price doubling after he joined the board. The activist pressure is amplified by other disgruntled shareholders, such as Cannell Capital, which also advocates for a board 'upgrade' citing poor execution. While OraSure has attempted to diversify through acquisitions like Sherlock Biosciences, it operates in a highly fragmented and competitive diagnostics market dominated by large-cap players, intensifying the need for a clear and effective corporate strategy. The convergence of a defined valuation gap (stock at $3.25 vs. a higher bid), public investor dissent, and a credible activist with a history of value creation suggests a high probability of a strategic or governance-related event at OraSure.

Key Decisions for Investors

• Consider the activist campaign by Altai Capital as a significant catalyst for unlocking value, as a proxy contest could force a strategic review or sale, potentially closing the gap between the current $3.25 stock price and the recently rejected $3.50-$4.00 buyout offer.
• Evaluate Rishi Bajaj's successful turnaround at ContextLogic as a credible, albeit not guaranteed, playbook for his potential impact at OraSure, and closely monitor Altai's specific board nominations and strategic proposals.
• Investors should weigh the potential upside from a board shakeup against the company's documented execution challenges and the intense competition OraSure faces from much larger incumbents in the diagnostics market.